The object of this study was to investigate the safety and clinical response of immunotherapy targeting the WT1 (Wilms' tumor 1) gene product in patients with gynecological cancer.
International Research and Educational Institute for Integrated Medical Sciences, Tokyo Women's Medical University, Tokyo, 162-8666, Japan. satoshi.ohno55@gmail.com
